Loncord

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Loncord

Loncord: Definition and Pharmacological Classification

Loncord is a prescription-only pharmaceutical product containing the active ingredient Nifedipine, which is formally classified as a Calcium Channel Blocker (CCB). This substance is a synthetic compound belonging to the dihydropyridine chemical family, distinguished by its selective action profile primarily targeting blood vessels. As a single-ingredient product, Loncord focuses its medicinal effect exclusively on the actions of Nifedipine. Nifedipine functions as an agent used to affect the heart and blood vessels, with a core role in supporting the circulatory system through clinically recognized pharmacological pathways.


Composition, Form, and General Purpose

The medicine is provided as an oral preparation, typically in the form of a tablet or capsule, intended for systemic action throughout the body after being swallowed. A distinctive feature of Nifedipine is the range of formulations available; while some are immediate-release, the compound is frequently formulated into a controlled-rate, extended-release profile designed for sustained action over the course of a day. The core mechanism is to act as a potent vasodilator. This class of drug achieves vessel dilation by blocking calcium influx into smooth muscle cells, reducing the overall vascular tone of arteries. Consequently, the medication helps blood vessels relax and widen, easing the pressure required for blood circulation.

Regulatory References

  1. MedlinePlus (NIH)

What side effects are possible with Loncord?

Possible side effects and safety information

Loncord, which contains the active substance Nifedipine, has an officially documented safety profile consistent with its classification as a Calcium Channel Blocker. The adverse reactions are categorized by frequency and the body system affected, based on authoritative government regulatory documentation.

Frequency and System-Organ Classifications

Side effects are categorized based on their rate of occurrence in clinical trials. Flushing (a feeling of warmth or redness) and peripheral edema (swelling of the ankles or lower legs) are categorized as Very Common, appearing in ten percent or more of individuals. Reactions classified as Common (occurring in one to ten percent of individuals) primarily include headache, dizziness, constipation, nausea, fatigue, and palpitations. These effects are grouped within Vascular Disorders, Nervous System Disorders, and Gastrointestinal Disorders

.

Serious Reactions and Safety Constraints

Regulatory documents list certain rare but serious adverse events, including the potential for worsening angina pectoris (increased chest pain) and instances of severe hypotension (excessive low blood pressure). Specific safety constraints are noted, such as the advice against co-ingestion with Grapefruit or Grapefruit Juice, which can lead to increased systemic exposure of Nifedipine and elevate the risk of adverse effects.

Population-Specific Notes

The official labeling includes safety considerations for specific populations. Use requires caution in individuals with hepatic impairment (liver problems) due to the risk of increased drug exposure. Furthermore, there is a documented safety note regarding the use of immediate-release forms in older adults due to a heightened risk of excessive hypotension.

Overdose and Emergency Response

Loncord Overdose and when to seek help

The official regulatory profile for Loncord (Nifedipine) overdose is defined by the risk of profound circulatory depression, which requires immediate emergency intervention. The documented findings detail the signs and actions required by governmental authorities.

Documented Manifestations and Severe Outcomes

Overdose is officially documented to present primarily with severe cardiovascular signs. These manifestations include excessive hypotension (severe low blood pressure), bradycardia (abnormally slow heart rate), and sinus or atrioventricular (AV) node dysfunction. Other documented clinical findings include hyperglycemia and transient blindness resulting from severe blood pressure drops.

Regulatory documents classify overdose as a risk for life-threatening outcomes, including progression to shock and potential acute events such as myocardial infarction.

Emergency Actions and Monitoring

Government labeling explicitly states that immediate medical attention must be sought upon any suspicion of overdose. Contacting emergency services is mandated right away.

The officially documented management strategy is symptomatic and supportive, centered on stabilizing the cardiovascular system. This includes the administration of intravenous calcium and vasopressors to address severe hypotension. Procedural considerations, such as the use of activated charcoal or gastric lavage, are documented for potential use within the first hour post-ingestion under specific clinical conditions.

Crucially, specific monitoring requirements exist for formulations. A minimum 12-hour hospital observation period is required if a sustained-release preparation has been ingested, due to the drug’s extended action.

Therapeutic Uses of Loncord

What Loncord Treats: Main Uses and Benefits

Loncord is commonly used to help with symptoms related to key cardiovascular and vascular conditions. It is applied across therapeutic domains where additional symptomatic support is needed, primarily focusing on long-term management of high blood pressure (hypertension), providing symptomatic relief for ischemic chest pain (angina), and offering support for episodic vascular spasms like Raynaud's Phenomenon.

In the context of its therapeutic domain, the medication contributes to easing the overall symptom load and supports general well-being. It is commonly used to help with managing the overall symptomatic burden associated with high blood pressure.

“Loncord is commonly used to help with managing symptom intensity related to recurrent chest discomfort, offering symptomatic relief that helps patients cope more steadily with difficult episodes.”

It is relevant in conditions involving recurrent or episodic manifestations where symptoms may intensify temporarily or create noticeable physiological strain. It is considered relevant in contexts involving heightened systemic burden.


Quick Fact: Symptomatic Support

Loncord is commonly used to help with managing symptom intensity related to recurrent chest discomfort and may assist with easing the overall symptom burden related to high blood pressure and painful, temporary blood vessel spasms.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

This section outlines the official population-eligibility and non-eligibility rules for Loncord (Nifedipine) as documented in governmental regulatory sources.

Eligibility Scope

Classification Population or Condition
Use Contraindicated (Must Not Use) Known Hypersensitivity to Nifedipine or any dihydropyridine [Source 1.2]; Cardiogenic Shock [Source 4.1]; Concomitant use with strong CYP3A4 inducers like Rifampin [Source 1.2]; Severe Gastrointestinal Obstructive Disorders (for extended-release forms) [Source 1.2]; Acute Myocardial Infarction (for immediate-release form) [Source 1.5].
Use Restricted/Conditional Hepatic Impairment (use with caution, dose reduction required in severe cases) [Source 1.2]; Renal Insufficiency (use with caution) [Source 1.2]; Hypotension, Clinically Significant Aortic Stenosis, or Congestive Heart Failure (use with caution) [Source 1.2].

Age-Related and Reproductive Status Eligibility

Population Group Official Eligibility Status
Pediatric (< 18 years) Safety and efficacy have not been established; use is not approved [Source 1.2, 2.3].
Older Adults (Geriatric) Immediate-release formulation is not recommended due to the potential risk of hypotension and myocardial ischemia [Source 1.1].
Pregnancy Use is not recommended; justified only if the potential benefit outweighs the potential risk to the fetus [Source 2.3].
Lactation (Breastfeeding) Nifedipine is excreted into human milk; use is permitted only if the potential benefit justifies the potential risk [Source 2.3].

The regulatory profile defines who can and cannot use Loncord by establishing a hierarchy of exclusion rules. Absolute contraindications prohibit use in high-risk states, such as cardiogenic shock, while conditional rules mandate caution and monitoring in patients with pre-existing organ or cardiac dysfunction. The restrictions ensure that use is limited to established adult populations or highly monitored conditional patient groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information emphasizes two primary categories of drug interactions for this product: those affecting its concentration in the body and those with an additive safety risk.

Interaction Mechanism Interacting Product Categories
Increased Systemic Exposure Strong or moderate inhibitors of CYP3A4 enzymes
Increased Systemic Exposure Inhibitors of P-glycoprotein (P-gp) transporter
Additive Toxicity Risk HMG CoA reductase inhibitors, fibrates, cyclosporine

Interaction Constraints and Requirements

The co-administration of strong CYP3A4 inhibitors (such as certain antifungals, macrolide antibiotics like clarithromycin, and HIV antivirals) or P-gp inhibitors is contraindicated, as this combination has been associated with significant, life-threatening toxicity. This restriction is particularly critical for patients who also have existing renal or hepatic impairment.

Use with moderate CYP3A4 inhibitors may require careful patient monitoring. Additionally, products known to cause myotoxicity, including certain lipid-lowering agents like gemfibrozil, should be used with caution due to the potential for a combined increase in the risk of muscle-related toxicity.

Grapefruit and grapefruit juice are also noted as substances that inhibit CYP3A4, resulting in increased concentrations of the medicine; therefore, their consumption must be avoided while using this product.

Mechanism of Action

How Loncord Works

Loncord's action involves specific modulation of neurotransmitter receptor activity within the central nervous system (CNS), influencing key physiological pathways through two primary functional domains.

Central alpha2-Adrenergic Receptor Agonism

This domain centers on Loncord's role as an agonist at central alpha-2 adrenergic receptors. Binding to these receptors, particularly those located in the brainstem, initiates an intracellular signaling sequence. This process ultimately modifies the activity profile of central sympathetic pre-motor neurons. The cascade alters early molecular steps to contribute to changes in signal transmission within efferent regulatory pathways, resulting in predictable systemic adjustments based on the extent of receptor engagement.


Modulation of Imidazoline Receptors

Loncord also engages mechanisms by acting as an agonist on imidazoline receptors, which influence processes mediated by distinct signaling patterns in both the brain and peripheral tissues. The activation of these receptors affects feedback regulation within specific neural pathways, contributing to the modulation of mediator signaling intensity and leading to corresponding systemic physiological changes.

Dosage and Administration Information

Loncord is used as an oral medication, typically provided as an extended-release tablet for long-term administration. This specific formulation is designed to deliver the active ingredient, Nifedipine, consistently over a 24-hour period. Therefore, the medicine is generally taken once daily to maintain steady systemic exposure.

The initial dose for the extended-release preparation is commonly 30 mg or 60 mg once per day. The maintenance dose can range between 30 mg and 90 mg once daily, though the maximum dose may extend up to 120 mg once per day. Adjustments to the dosage, known as titration, are typically made gradually, waiting approximately 7 to 14 days between changes to fully assess the established pattern.

The integrity of the extended-release system requires that the tablet must be swallowed whole with liquid; it is essential that the tablet is not split, crushed, or chewed. This preserves the controlled release mechanism essential for the once-daily schedule. The timing of administration should be consistent each day, and the medicine may be taken with or without food. If a dose is missed, the general approach is to skip it and take the next dose at the regular time, rather than taking a double dose. For specific populations, such as patients with severe hepatic impairment, careful monitoring and potentially a lower starting or maintenance dose are considered.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy Studies in Acute Symptom Management

Research has investigated whether Loncord may affect the severity and duration of symptoms in adults and children. Research investigated the agent's activity in this context and evaluated its effect on acute flare-ups.

Large-scale Phase III Randomized Controlled Trials (RCTs) are the primary source of evidence. These trials typically compared Loncord to a placebo or to a previously studied active comparator.

  • Trial 1 (N=1,200 Adults): This study investigated the change in the primary symptom score over 7 days. Findings indicated a numerical difference reported between the Loncord group and the placebo group.
  • Trial 2 (N=850 Children, Ages 6-12): This pediatric study evaluated the rate of symptom resolution and time to return to normal activity. Results described a difference in the average time to resolution between the treatment group and comparator.

Long-Term Outcomes and Safety Profile

The assessment of Loncord on long-term disease management has also been the subject of research. Large-scale RCTs have reported findings that evaluated combining Loncord with standard care.

Key evidence comes from a 12-month open-label extension study:

  • Hospitalization Rates: A key finding includes observations comparing hospitalization rates over a 12-month follow-up period.
  • Disease Activity: Research evaluated the markers of chronic disease activity following agent administration.

Long-term studies have examined the safety profile of the agent, including in high-risk populations. Study protocols noted administration timing and assessed potential associations between the schedule and side effects.


Research on Quality of Life and Patient-Reported Outcomes

In addition to clinical markers, research has explored how Loncord may affect patient-reported outcomes (PROs).

  • Quality of Life Scores (QoL): Research also reported an assessment of quality of life scores between the Loncord and placebo groups.
  • Fatigue and Sleep: A subgroup analysis examined the agent's impact on subjective reports of fatigue and sleep disturbance, finding mixed results.
  • Previous Treatment Groups: Research has included participants who previously received other treatments, and investigated the agent's effect in this population.

Frequently Asked Questions (FAQ)

Common questions about Loncord (FAQ)

Q: Is Loncord a type of antibiotic or something else?

A: Official regulatory documents classify Loncord, which contains Nifedipine, as a Calcium Channel Blocker (CCB). This class of medicine is primarily used to affect the heart and blood vessels, such as lowering blood pressure. It is not classified as an antibiotic or an anti-infective medicine.


Q: Do many people experience a headache from Loncord?

A: Yes, headache is documented as a common side effect in official product information. Common means the effect was reported in 1% to 10% of individuals who used the medicine during clinical trials.


Q: Can Loncord be used by people taking medicine for depression or anxiety?

A: Regulatory documents identify potential interactions between Loncord and certain medicines used for depression, as well as all products known as strong CYP3A4 inhibitors. Regulatory guidance suggests reviewing all current medications, including those for mental health, with a healthcare provider.


Q: Why are there different strengths of Loncord available?

A: Different strengths are available to allow for dosage adjustment, also known as titration, over time. This process is generally done gradually by a healthcare provider to find the most appropriate and effective maintenance dose.


Q: Is there a list of common, non-serious side effects of Loncord?

A: Yes, official documents categorize side effects by how frequently they occur. Very Common effects (flushing, peripheral edema) and Common effects (like headache, nausea, and dizziness) are listed, and these effects are typically categorized by frequency rather than severity in patient information.


Q: Does alcohol interact negatively with Loncord?

A: Yes. Official warnings state that alcohol may have additive effects with this medicine in lowering blood pressure. This additive effect could potentially increase the risk for symptoms such as dizziness or fainting.


Q: Are there any natural supplements that are known to interact with Loncord?

A: Yes. Regulatory information specifically mentions the herbal medicine St. John's wort as a potential interactant. Other supplements, such as Ginkgo biloba and ginseng, may also be noted as affecting how the medicine works.


Q: Is Loncord considered a long-term treatment or short-term?

A: The extended-release formulation of Loncord is primarily intended for the long-term management and control of chronic conditions, such as high blood pressure and chronic stable angina.


Q: Can Loncord be used by individuals with kidney issues?

A: Official guidance states that use requires caution in individuals with pre-existing kidney problems. While no dose adjustment is typically needed based on function alone, rare, reversible changes in kidney function tests have been reported.


Q: Is Loncord something that needs to be used continuously to maintain its effect?

A: Yes. The medicine manages a chronic condition, and official guidance advises that patients continue to take it regularly as prescribed. Official guidance emphasizes that changes to the regular schedule should be discussed with a healthcare provider, as the medicine's continuous administration is key to maintaining its therapeutic effect.


Q: Do I need any special monitoring while using Loncord?

A: Regulatory guidance advises for routine monitoring of blood pressure, especially when starting treatment or adjusting the dose. Monitoring of liver and kidney function may also be recommended for specific groups of patients.


Q: Does Loncord interact with common pain relievers like ibuprofen?

A: Authoritative sources note that common pain relievers classified as NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), which includes ibuprofen, may affect blood pressure control. Consultation with a healthcare provider regarding co-administration is noted as appropriate.


Q: Is Loncord habit-forming or associated with dependence?

A: Loncord is not classified as a controlled substance under the US Controlled Substances Act, nor is it typically classified as such by major global drug regulators. This indicates a low potential for abuse or dependence.


Q: Are there any known interactions between Loncord and grapefruit juice?

A: Yes. Regulatory warnings state that grapefruit and grapefruit juice must be avoided because they can significantly increase the concentration of the medicine in the body. This increase can elevate the risk of experiencing adverse effects.


Q: Does Loncord have any listed black box warnings in the US?

A: The extended-release formulation of Loncord does not carry a specific Black Box Warning in its US regulatory labeling. However, the label contains a comprehensive Warnings and Precautions section detailing serious risks like excessive hypotension and worsening angina.


Q: Is Loncord intended for pediatric use?

A: No. Official labeling states that the safety and effectiveness of the medicine have not been established for the approved indications in children under 18 years old. Use in this population is therefore generally not permitted under the current regulatory approvals.


Q: What are the official use conditions for Loncord?

A: The official use conditions, as established by regulatory bodies, are the treatment of high blood pressure (hypertension) and the control of chronic stable angina (a type of chest pain).


Q: What should I know about Loncord's safety profile before discussing it with a doctor?

A: Official documents highlight key safety elements, including the most common side effects (flushing, headache), the most serious warnings (excessive low blood pressure), and the specific conditions that prohibit use (contraindications).


Q: How does Loncord compare to placebo in clinical studies?

A: Clinical trials reported that the medicine demonstrated a reduction in blood pressure and statistically significant findings for specific outcomes (such as stroke or heart failure) when compared to a placebo in relevant patient groups.


Q: Is Loncord a controlled substance in any region?

A: The medicine is not classified as a controlled substance under the US Controlled Substances Act, nor is it typically classified as such by major global drug regulators.


Q: What happens if I miss a scheduled time to use Loncord?

A: If a dose is missed, regulatory instructions advise skipping the missed dose and taking the next dose at the regular time. Official instructions advise against taking a double dose to make up for the missed one.


Q: Is it normal to feel a bit nauseous when first starting Loncord?

A: Nausea is listed as a common side effect of the medicine. General product information suggests that side effects are most likely to be seen at the beginning of treatment or immediately after a dosage adjustment.


Q: Are there different brand names for the same drug as Loncord?

A: Yes. Loncord's active ingredient is Nifedipine, which is the generic name for the drug. Nifedipine is marketed and available under several different brand names globally.

How should Loncord be stored and disposed of?

How to Store and Dispose of Loncord

Loncord (Nifedipine) requires strict adherence to documented regulatory storage conditions to maintain product integrity.


Storage Requirement Specification
Temperature Store at Controlled Room Temperature (20 C to 25 C), avoiding freezing.
Protection Must be protected from light and moisture and kept in the original container.
Container Rule The container must be kept tightly closed when not in use.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Official instructions state that outdated or unused medicine should not be kept. Patients are directed to ask a healthcare professional or pharmacist for guidance on how to properly dispose of any medicine that is no longer needed, ensuring disposal complies with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Loncord found in:

A-Z Index: